Abstract Number: 541 • 2019 ACR/ARP Annual Meeting
Multicenter, Evaluator-blinded, Randomized, Non-inferiority Study, to Assess the Efficacy, Safety and Immunogenicity of Etanercept Biosimilar (EtaBS) vs. Reference Etanercept (EtaRef) in Combination with Methotrexate for the Treatment of Patients with Rheumatoid Arthritis
Background/Purpose: Enerceptan® (EtaBS) has been developed as a proposed biosimilar of etanercept. Phase I study demonstrated pharmacokinetic equivalence with EtaRef.Methods: A multicenter, non-inferiority, randomized, assessor -blinded,…Abstract Number: 592 • 2018 ACR/ARHP Annual Meeting
Improved Response to Etanercept Is Associated with Serum Vitamin D Levels in Rheumatoid Arthritis
Background/Purpose: Although treatment of rheumatoid arthritis (RA) has significantly improved during the past decades, many patients do not adequately respond or become resistant to current…Abstract Number: 2994 • 2018 ACR/ARHP Annual Meeting
Costs Associated with Non-Medical Switching from Originator to Biosimilar Etanercept in Patients with Rheumatoid Arthritis in the UK
Background/Purpose: To estimate the cost impact of non-medical switching from originator etanercept (ETN) to biosimilar ETN in patients with rheumatoid arthritis (RA) in the UK.…Abstract Number: 2441 • 2017 ACR/ARHP Annual Meeting
A Phase III, Multicenter, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Similarities between LBEC0101 and Etanercept Reference Product in Terms of Efficacy and Safety in Patients with Active Rheumatoid Arthritis Inadequately Responding to Methotrexate
Background/Purpose: LBEC0101 has been developed as a biosimilar to the etanercept reference product (ETN-RP). This study was to evaluate the similarities between LBEC0101 and ETN-RP…Abstract Number: 2447 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Tolerability of Benepali in Rheumatoid Arthritis Patients Switched from Enbrel
Background/Purpose: Benepali, the etanercept biosimilar, is licenced in the UK for rheumatoid arthritis (RA) and costs less than Enbrel. This study aimed to evaluate the…Abstract Number: 2797 • 2017 ACR/ARHP Annual Meeting
Etanercept Biosimilar GP2015 Has Equivalent Efficacy and Safety to Etanercept Originator in Patients with Moderate to Severe Rheumatoid Arthritis: The Phase 3 Equira Study
Background/Purpose: The biosimilarity of GP2015 and etanercept originator product (ETN) has been previously demonstrated in patients with chronic plaque-type psoriasis.1 The randomized, double-blind, phase 3…Abstract Number: 2526 • 2016 ACR/ARHP Annual Meeting
TNF Blocker Concentrations or Detection of Antibodies Against Anti-TNF before a Tapering Process Are Not Predictive to Relapse
Background/Purpose: The goal of rheumatoid arthritis (RA) strategy is to reach remission or at least a low disease activity. When this goal is reached, no…Abstract Number: 2579 • 2016 ACR/ARHP Annual Meeting
Etanercept Treatment Does Not Adversely Affect Traditional Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular (CV) disease. This analysis evaluated changes in metabolic and lipid CV risk factors…Abstract Number: 591 • 2016 ACR/ARHP Annual Meeting
Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
Background/Purpose: When a tumor necrosis factor inhibitor (TNFi) fails in a patient with moderate to severe rheumatoid arthritis (RA), new American College of Rheumatology (ACR)…Abstract Number: 477 • 2015 ACR/ARHP Annual Meeting
On-Demand Use of Etanercept Only for Disease Flares Reduced the Disease Activity Score and Structural Damage Equivalent to Fully-Use of Etanercept in RA Patients
Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) are essential in the treatment of rheumatoid arthritis (RA). Biological DMARDs are particularly recommended for patients with active RA…Abstract Number: 540 • 2015 ACR/ARHP Annual Meeting
Clinical Relevance of Etanercept Levels and Anti-Etanercept Antibodies in Long-Term Treatment of Rheumatoid Arthritis Patients
Background/Purpose: Biological compounds have belonged to the therapeutic options for the treatment of rheumatoid arthritis for about 15 years. The application of biological substances is…Abstract Number: 598 • 2015 ACR/ARHP Annual Meeting
Economic Impact of Decreasing Adalimumab and Etanercept Doses and Drug Monitoring in Patients with Rheumatoid Arthritis in Clinical Remission: Preliminary Study from a Local Biologics Unit
Background/Purpose: To evaluate the economic impact of adalimumab (ADL) and etanercept (ETN) dose reduction (by decreasing treatment frequency) and drug monitoring in patients with rheumatoid…Abstract Number: 2739 • 2015 ACR/ARHP Annual Meeting
Survival of Etanercept (ETN) Responders after Methotrexate (MTX) Failure When ETN Is Initiated As Mono or Combination Therapy or after MTX Withdrawal from ETN/MTX Combination in Long Standing Rheumatoid Arthritis (RA). a Single Center Retrospective Study
Background/Purpose: The long term sustainability of ETN as monotherapy (mono) or in combination (combo) with methotrexate (MTX) is uncertain in patients with longstanding RA responding…Abstract Number: 2924 • 2014 ACR/ARHP Annual Meeting
Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis
Background/Purpose Up to 40% of RA patients on anti-TNF treatment fail to respond either due to primary inefficacy or loss of response. One explanation is…Abstract Number: 2418 • 2014 ACR/ARHP Annual Meeting
Treatment Pattern and Direct Cost of Biologics for Rheumatoid Arthritis Patients: A Real-World Analysis of Nationwide Japanese Claims Data
Background/Purpose Biologics such as etanercept (ETN), adalimumab (ADA), infliximab (IFX) and tocilizumab (TCZ) have led dramatic improvement in the treatment of rheumatoid arthritis (RA), but…